TipRanks
Advertisement
Advertisement

DE:NP5 Stock Latest News

Newron Pharma price target lowered to CHF 19 from CHF 35 at Roth Capital
The FlyNewron Pharma price target lowered to CHF 19 from CHF 35 at Roth Capital
3d ago
Newron Faces Ongoing FDA Hold on U.S. Arm of Key Evenamide Schizophrenia Trial
PremiumCompany Announcements
Newron Faces Ongoing FDA Hold on U.S. Arm of Key Evenamide Schizophrenia Trial
12d ago
Newron Bolsters Finances as Evenamide Phase 3 Program Advances Toward 2027 Readouts
PremiumCompany Announcements
Newron Bolsters Finances as Evenamide Phase 3 Program Advances Toward 2027 Readouts
16d ago
Newron Ramps Up Evenamide Phase 3 as Financing and Patent Wins Offset Wider Loss
PremiumCompany Announcements
Newron Ramps Up Evenamide Phase 3 as Financing and Patent Wins Offset Wider Loss
16d ago
Newron secures EUR 5.5 million tranche to fund Phase 3 Evenamide program
PremiumCompany Announcements
Newron secures EUR 5.5 million tranche to fund Phase 3 Evenamide program
30d ago
Newron Bolsters Phase 3 Schizophrenia Program with EUR 5.5 Million Share Subscription
PremiumCompany AnnouncementsNewron Bolsters Phase 3 Schizophrenia Program with EUR 5.5 Million Share Subscription
30d ago
Newron completes pivotal Phase 3 recruitment for Evenamide in treatment-resistant schizophrenia
Premium
Company Announcements
Newron completes pivotal Phase 3 recruitment for Evenamide in treatment-resistant schizophrenia
1M ago
Newron Advances Pivotal Phase 3 Trial of Schizophrenia Candidate Evenamide
Premium
Company Announcements
Newron Advances Pivotal Phase 3 Trial of Schizophrenia Candidate Evenamide
1M ago
Newron, FDA in constructive talks over U.S. trial halt for schizophrenia drug Evenamide
PremiumCompany Announcements
Newron, FDA in constructive talks over U.S. trial halt for schizophrenia drug Evenamide
3M ago
Newron Pharma price target lowered to CHF 44 from CHF 48 at H.C. Wainwright
PremiumThe Fly
Newron Pharma price target lowered to CHF 44 from CHF 48 at H.C. Wainwright
5M ago
PremiumCompany Announcements
FDA halts U.S. recruitment in Newron’s key schizophrenia trial after patient death
5M ago
PremiumCompany Announcements
Newron Shareholders Back Board Changes at 2026 General Meeting
6M ago
Newron Pharmaceuticals’ Earnings Call Signals Pivotal Year Ahead
PremiumCompany AnnouncementsNewron Pharmaceuticals’ Earnings Call Signals Pivotal Year Ahead
7M ago
Newron Pharma price target raised to CHF 48 from CHF 43 at H.C. Wainwright
Premium
The Fly
Newron Pharma price target raised to CHF 48 from CHF 43 at H.C. Wainwright
7M ago
Newron bolsters finances as Evenamide enters pivotal global Phase III
Premium
Company Announcements
Newron bolsters finances as Evenamide enters pivotal global Phase III
7M ago
Newron Fortifies Evenamide Phase III Push with Fresh Capital, Patent Win and Board Overhaul
PremiumCompany Announcements
Newron Fortifies Evenamide Phase III Push with Fresh Capital, Patent Win and Board Overhaul
7M ago
Newron to Highlight Phase III Evenamide Data at 2026 Schizophrenia Congress
PremiumCompany Announcements
Newron to Highlight Phase III Evenamide Data at 2026 Schizophrenia Congress
7M ago
Newron extends EIB loan maturities to align financing with Evenamide milestones
PremiumCompany Announcements
Newron extends EIB loan maturities to align financing with Evenamide milestones
7M ago
Newron refreshes board with CNS and capital markets experts ahead of AGM
PremiumCompany Announcements
Newron refreshes board with CNS and capital markets experts ahead of AGM
7M ago
Newron Raises Up to EUR 38 Million to Advance Phase III Schizophrenia Drug Evenamide
PremiumCompany AnnouncementsNewron Raises Up to EUR 38 Million to Advance Phase III Schizophrenia Drug Evenamide
8M ago
Newron Raises Up to EUR 38 Million to Advance Phase III Schizophrenia Drug
Premium
Company Announcements
Newron Raises Up to EUR 38 Million to Advance Phase III Schizophrenia Drug
8M ago
Newron’s Evenamide Shows Durable Benefits as Add-On Therapy in Treatment-Resistant Schizophrenia
Premium
Company Announcements
Newron’s Evenamide Shows Durable Benefits as Add-On Therapy in Treatment-Resistant Schizophrenia
8M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >